RBC Balanced Immuno-inflammatory Signatures Identify Advanced Breast Cancer Patients on CDK4/6 Inhibitors at Increased Risk of Progression and Death
Published: 4 March 2025| Version 1 | DOI: 10.17632/6xhbthd425.1
Contributor:
Jiayi MaDescription
This is the serum metabolomics data of hormone receptor positive advanced cancer patients before receiving CDK4/6 inhibitor treatment. The code for analysis is attached.
Files
Steps to reproduce
The metabolite data was obtained through liquid chromatography-tandem mass spectrometry.
Categories
Breast Cancer, Metabolomics